港股异动 | 励晶太平洋(00575)一度飙升110% 旗下创新药Senstend™获国家药监局上市批准

智通财经06-17

智通财经APP获悉，励晶太平洋(00575)今日一度飙涨超110% ，截至发稿，涨80.7%，报1.03港元，成交额264.96万港元。消息面上，励晶太平洋宣布，旗下创新疗法 Senstend™ 的新药申请已正式获得国家药品监督管理局的上市批准，并附带为期四年数据保护期。此次获批将立即为集团注入显著的现金流与财务回报。根据独家许可协议，国家药品监督管理局的上市批准已触发商业战略合作伙伴江苏万邦生化...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2644182357?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-17 13:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644182357","market":"us","top_or_hot":-1,"title":"港股异动 | 励晶太平洋(00575)一度飙升110% 旗下创新药Senstend™获国家药监局上市批准","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，励晶太平洋(00575)今日一度飙涨超110% ，截至发稿，涨80.7%，报1.03港元，成交额264.96万港元。消息面上，励晶太平洋宣布，旗下创新疗法 Senstend™ 的新药申请已正式获得国家药品监督管理局的上市批准，并附带为期四年数据保护期。此次获批将立即为集团注入显著的现金流与财务回报。根据独家许可协议，国家药品监督管理局的上市批准已触发商业战略合作伙伴江苏万邦生化...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1455422.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 励晶太平洋(00575)一度飙升110% 旗下创新药Senstend™获国家药监局上市批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 励晶太平洋(00575)一度飙升110% 旗下创新药Senstend™获国家药监局上市批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-17 13:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1455422.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，励晶太平洋(00575)今日一度飙涨超110% ，截至发稿，涨80.7%，报1.03港元，成交额264.96万港元。消息面上，励晶太平洋宣布，旗下创新疗法 Senstend™ 的新药申请已正式获得国家药品监督管理局的上市批准，并附带为期四年数据保护期。此次获批将立即为集团注入显著的现金流与财务回报。根据独家许可协议，国家药品监督管理局的上市批准已触发商业战略合作伙伴江苏万邦生化...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1455422.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1455422.html","article_id":"2644182357","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644182357","pubTimestamp":1781675740,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，励晶太平洋今日一度飙涨超110% ，截至发稿，涨80.7%，报1.03港元，成交额264.96万港元。消息面上，励晶太平洋宣布，旗下创新疗法 Senstend 的新药申请已正式获得国家药品监督管理局的上市批准，并附带为期四年数据保护期。此外，随着江苏万邦医药预计将于2026年下半年启动首次商业销售，届时将再度触发向励晶太平洋支付200万美元。因此，集团预计将于2026年内稳健收取合共700万美元的现金付款。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","IPOS":"Renaissance International IPO ETF","06978":"永泰生物-B","BK4585":"ETF&股票定投概念","BK4588":"碎股","00575":"励晶太平洋","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Hong Kong stock changes | Regent Pacific (00575) once soared 110%, its innovative drug Senstend ™ Obtained marketing approval from the NMPA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"00575":1.5,"IPOS":1.5,"VXUS":1.5,"06978":1.5},"content_text":"智通财经APP获悉，励晶太平洋(00575)今日一度飙涨超110% ，截至发稿，涨80.7%，报1.03港元，成交额264.96万港元。消息面上，励晶太平洋宣布，旗下创新疗法 Senstend™ 的新药申请已正式获得国家药品监督管理局的上市批准，并附带为期四年数据保护期。此次获批将立即为集团注入显著的现金流与财务回报。根据独家许可协议，国家药品监督管理局的上市批准已触发商业战略合作伙伴江苏万邦生化医药集团有限责任公司(江苏万邦医药，为上海复星医药(集团)的完全控股公司)向励晶太平洋支付500万美元(约3900万港元)的款项。此外，随着江苏万邦医药预计将于2026年下半年启动首次商业销售，届时将再度触发向励晶太平洋支付200万美元(约1560万港元）。因此，集团预计将于2026年内稳健收取合共700万美元(约5460万港元)的现金付款。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644182357","isCrawlerRequest":true}